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Previewsto the importance of CSCs while sup-
porting Tlx as a novel glioma CSC
marker and expanding opportunities
to investigate regulators of CSCs in a
genetic model. The combined use of
this powerful model with well character-
ized human tumor models should inform
the discovery of other CSC points of
fragility and could provide a useful tool
to detect the initial stages of brain
cancer. Although the CSC hypothesis
does not comprehensively explain all
of tumor biology, CSCs as roots of
many cancers represent an added level
of complexity in tumors, a challenge
we must face in trying to develop more
effective therapeutics.116 Cell Stem Cell 15, August 7, 2014 ª2014REFERENCES
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Somatic cells can be reprogrammed to induced pluripotent stem cells via exogenous expression of a small
set of transcription factors, but the regulatory mechanisms controlling this cell transition are poorly under-
stood. Two recent reports demonstrate the value of RNAi screens as a tool to uncover roadblocks in this
inefficient process.Groundbreaking work by Takahashi and
Yamanka has demonstrated that applying
a defined set of transcription factors
(Oct4, Sox2, Klf4, and c-Myc; OSKM)
can result in the conversion of somatic
cells into induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka,
2006). This method has shown its robust-
ness and reproducibility—it has been
applied to a wide variety of species and
cell types including human cells (reviewed
in Theunissen and Jaenisch, 2014). It is
not surprising that since its discovery the
processes involved in the generation
of iPSCs have been studied intensively.
However, in comparison to somatic cell
nuclear transfer, direct reprogramming is
still a slow and inefficient process, indi-cating that cellular barriers are hampering
the conversion of a committed and
specialized cell into an immature and
pluripotent iPSC. Different studies in
mouse and human reprogramming have
highlighted a key role of the epigenetic
state in regulating reprogramming. How-
ever, other pathways, including TGF-b or
p53 signaling, have also been implicated
in hampering the generation of iPSCs
(reviewed in Theunissen and Jaenisch,
2014), indicating that several different
cellular processes can influence the
speed and efficiency of iPSC generation.
The identification of additional pathways
involved in reprogramming would no
doubt further enhance our understanding
of underlying mechanisms guiding re-programming. In recent issues of Cell
and Cell Reports, the groups of Ram-
alho-Santos and Rana report genome-
wide RNAi screens to delineate new
factors that affect reprogramming effi-
ciency and kinetics using human and
mouse fibroblasts, respectively, as the
starting cell types (Qin et al., 2014, Yang
et al., 2014).
Qin et al. applied the RNAi screen em-
ploying an ultracomplex library of shRNAs
in combination with next generation
sequencing (NGS) to identify roadblocks
to human cellular reprogramming. They
used a lentiviral library encompassing
600,000 shRNAs targeting almost 20,000
genes and transduced these together
with the OSKM factors and p53 RNAi
Figure 1. Illustration of the Roadblocks during Reprogramming
Biological processes that constitute barriers prevent successful reprogramming (red arrows). Combinatorial inhibition lowers the barrier, allowing more cells to
overcome the roadblocks (green arrows).
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Previewsinto human fibroblasts. FACS sorting after
28 days of Tra-1-81-positive iPSCs
and Tra-1-81-negative cells followed by
amplification of the shRNA sequences
and NGS then revealed enriched shRNAs
in the Tra-1-81-positive cells. For hit call-
ing the authors developed a method of
combining results from multiple shRNAs
targeting the same gene. The advantage
of this approach is that the multiobjective
optimization algorithm takes into account
the collective shRNA activity and the
number of enriched shRNAs. The large
complexity of the library makes it virtually
impossible to test every shRNA sequence
in multiple iPSC colonies. On the other
hand, the high complexity of the shRNA
library with on average 30 shRNA per
gene provides a large collection to identify
the best working shRNAs for individual
genes. However, as a note of caution,
the likelihood of identifying two shRNAs
with a similar off-target effect increases
in step with increasing complexity of
the library. Stringent validation with inde-
pendent silencing triggers, rescue experi-
ments, or both are therefore warranted
(Echeverri et al., 2006).
The authors were able to nominate
almost 1,000 candidate hits, which
they present in an associated web
page (http://songlab.ucsf.edu/ipsScreen/index.html). Clustering their screening
hits based on comparative analysis
together with publicly available time-
course gene expression and epigenetic
data allowed the authors to nominate
ubiquitination, endocytosis, vesicular
transport, and cell adhesion as pro-
cesses implicated in reprogramming
(Figure 1). Depletion of factors involved
in clatherin-specific endocytosis en-
hanced reprogramming at an early stage
and was linked to TGF-b signaling, a
known barrier in the generation of
iPSCs. Importantly, enhanced reprog-
ramming was also confirmed with the
clathrin-specific small molecule inhibitors
Pitstop1 and Pitstop2. Remarkably, the
combination of the drugs with some
candidate factors synergistically further
elevated the reprogramming efficiency
up to 15-fold.
In contrast to Qin et al., who per-
formed their study starting with human
fibroblasts, Rana and colleagues aimed
to identify mechanisms influencing re-
programming in mouse fibroblasts by
combining an RNAi screen together with
transcriptome analyses (Yang et al.,
2014). The authors employed a scarcely
specified shRNA library and sorted four
populations based on Thy1, SSEA-1,
and DsRed marker combinations (Theu-Cell Stem Cell 1nissen and Jaenisch, 2014) before ampli-
fication and NGS to identify enriched
or depleted shRNAs. They discover a
variety of sources for induced reprog-
ramming and cell-fate manipulation,
including genes implicated in cytoskel-
eton rearrangements (Figure 1), which
seem to be important during late-stage
reprogramming (Sakurai et al., 2014).
Interestingly, more than 50% of the
identified genes do not change their
expression levels during the reprogram-
ing procedure, indicating that important
factors guiding reprogramming do not
necessarily have to be differentially ex-
pressed at the transcriptional level. This
is an important finding, because many
scientists focus their attention on genes
that change expression levels in the
biological process that they study.
However, genes that do not change
expression levels might be equally impor-
tant modulators, which can be uncov-
ered by the unbiased approach of RNAi
screening.
Taken together, both studies signifi-
cantly increase the number of genes
that act as roadblocks during cellular re-
programming. Many of the known re-
programming roadblocks have important
functions during cancer initiation and
progression (Friedmann-Morvinski and5, August 7, 2014 ª2014 Elsevier Inc. 117
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PreviewsVerma, 2014). Somatic cells likely mount
barriers to reprogramming to avoid
cellular transformation. Hence, it will be
interesting to see whether newly iden-
tified roadblocks are also implicated in
cancer development. At the moment it
is unclear whether the small overlap of
hits between the two studies is due
to the species difference, the different
markers used to isolate cell populations,
or the studies not being comprehensive.
In support of the latter explanation, it
should be noted that several known re-
programming factors were not identified
in the screens. For instance, in a similar
approach Rais et al. found that Mbd3
RNAi together with OSKM transduction
results in deterministic and synchronized
iPSC reprogramming (Rais et al., 2013).
However, Mbd3 was identified in neither
the Qin et al. nor the Yang et al. studies.
Therefore, extended RNAi screens will
likely uncover even more genes that influ-
ence the efficiency and kinetics of iPSC
generation. In any event, the presented
data should broaden our understanding
of the underlying mechanisms of reprog-
raming. The challenging part will now
be to combine reprogramming barriers
whose combinatorial inhibition will have118 Cell Stem Cell 15, August 7, 2014 ª2014the largest impact on enhancing reprog-
ramming efficacy and kinetics. In addi-
tion, it will be important to see whether
the identified factors are fibroblast spe-
cific or if they are also roadblocks for
reprogramming in other somatic cells.
Recent studies have revealed contradict-
ing results for factors implicated in
reprogramming, where one group has
found that Mbd3 depletion promotes re-
programming (Rais et al., 2013), whereas
another group described that Mbd3
is required for efficient reprogramming
(Dos Santos et al., 2014). There were a
number of differences between the two
experimental approaches that might ac-
count for this discrepancy. Nevertheless,
this example illustrates the necessity
to conduct detailed experiments under
varying conditions to investigate the
molecular mechanisms that operate
during reprogramming. Therefore, the
development of an optimized protocol
demands a careful downstream anal-
ysis and a thorough investigation of
the reprogrammed iPSCs, including the
evaluation of their functionality as well
as the verification of their genomic and
epigenomic integrity (Liang and Zhang,
2013).Elsevier Inc.REFERENCES
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Tumorigenesis is a complex and poorly understood process in which oncogenes can activate competing
proapoptotic and proneoplastic programs. A recent paper in Cancer Cell demonstrates a dual role of the
MTDH-SND1 complex in suppressing the apoptotic response and promoting breast cancer development,
suggesting a new therapeutic avenue.Tumorigenesis is a complex process in
which cells typically acquire mutations
that do not initially alter their biology, but
ultimately lead to their transition into a
state characterized by the possession ofself-perpetuating, malignant properties.
Several distinct molecular programs may
contribute to this transition, but our
knowledge of this aspect of oncogenesis
is poor, particularly in epithelial carci-nomas that are frequently not detected
until after they are well established and
often disseminated. Elucidating the rele-
vant events that influence the speed and
ability of individual cells to achieve this
